Artelo ($ARTL) Stock Hub: After the Reverse Split, Can Q4 Data Outrun the Funding Risk?

01Latest verified status: the 1-for-9 reverse split announced on August 27

The new quarter improves the scientific narrative around ART26.12 but worsens the financial starting point. Management highlighted favorable single-ascending-dose safety, linear and dose-proportional pharmacokinetics, exposures above projected therapeutic levels and no human-specific metabolite concern. Those are useful Phase 1 de-risking observations. They do not demonstrate analgesic efficacy in patients, and the next study is still a healthy-volunteer multiple-dose experiment.

Financially, cash and investments fell from $10.3 million at March 31 to $4.2 million at June 30, a decline of $6.1 million within the quarter. Operating cash use over the whole first half was $6.2 million and financing provided $9.8 million in the same six months, so the quarterly movement and the half-year flows have to be read separately. Q2 R&D was $0.9 million, G&A was $1.6 million and net loss was $2.4 million, or $0.89 per share. Because the company has no product revenue and explicitly says additional capital is required, the clinical calendar cannot be analyzed separately from funding.

Research posture: preliminary, financing-constrained watchlist. Confidence is high in filed cash, expenses and share counts; moderate in near-term milestone timing; low-to-moderate in clinical efficacy because the most discussed efficacy dataset is a sponsor interim analysis with only five patients at the highest dose and six on placebo.

September 5 review: split trading is now effective, the August 20 amendment and patent allowance are incorporated, and no newer SEC filing appears after August 27 in the submissions feed. The investor website lists a September 1 presentation, but its PDF returned an access error; its contents are not claimed as verified here.

02Executive summary and the central investment debate

Artelo is a micro-cap clinical-stage biotechnology company attempting to create drugs around lipid signaling. The portfolio has three distinct economic profiles. ART27.13 is the most clinically advanced and the clearest partnering asset, but its CAReS evidence is small and incomplete. ART26.12 has a differentiated mechanism and clean first-in-human single-dose data, yet efficacy remains entirely nonclinical. ART12.11 is wholly owned and patent-protected, but has not entered human testing.

The decision hinge: can Artelo convert one of its 2026 milestones into fundable evidence or non-dilutive economics before another low-price capital raise dominates the cap table? DREAM is the cleanest near-term experiment because third parties fund the study. ART26.12 is the most scientifically differentiated owned development platform. ART27.13 is the most mature asset but needs a complete dataset, a development plan and ideally a partner.

What appears priced in: severe financing probability, limited confidence in the CAReS interim analysis, weak institutional sponsorship and a meaningful chance that further reverse splits or low-price issuance will be required. What is not safely priced: the size of any future raise, the ownership transferred through the equity line, and whether the Q4 milestones arrive before the liquidity constraint tightens further.

No price target is set here. A conventional discounted-cash-flow or rNPV output would create false precision because the company has not disclosed a pivotal design, registrational endpoint package, development budget, launch timing or reliable commercial assumptions for its lead programs.

03Company overview: one platform idea, three very different programs

Artelo Biosciences is a Nevada corporation headquartered in Solana Beach, California, with operating subsidiaries in the United Kingdom, Ireland and Canada. It has never generated product revenue. Its stated scientific focus is modulation of lipid-signaling pathways, including the endocannabinoid system and intracellular fatty-acid transport. That umbrella is broad enough to connect the portfolio scientifically, but the individual assets should be underwritten separately.

The company’s apparent breadth creates two opposite interpretations. It can be a collection of low-cost options around a coherent lipid biology platform. It can also be a sign that a very small organization is spreading scarce capital across too many indications before one program has a validated clinical endpoint. The correct reading depends on disciplined prioritization, external funding and licensing—not the number of diseases named in press releases.

Artelo’s investable business model is therefore not near-term commercialization. It is to produce enough human evidence to license or partner assets while preserving cash. The operating question is whether counterparties view the evidence as transaction-ready. The equity question is whether Artelo can reach that point without repeatedly recapitalizing at distressed prices.

04Timeline: how the ARTL thesis reached this point

A pattern repeats through the timeline: program news is frequently followed by financing activity, and target dates have moved. ART26.12’s MAD study was once discussed for Q4 2025 and is now planned for Q4 2026. ART12.11’s first-in-human timing also shifted. Milestone guidance should therefore be treated as a checkpoint to verify, not as completed execution.

05ART27.13: mechanism, history and economic rights

ART27.13 is a benzimidazole small molecule designed to agonize cannabinoid CB1 and CB2 receptors outside the central nervous system. The investment logic is that peripheral receptor activity could influence appetite, metabolism, muscle preservation and ocular physiology while avoiding the psychotropic effects that have limited centrally active cannabinoids. “Peripherally selective” is a pharmacologic objective, not proof that systemic or central adverse effects cannot occur at therapeutic exposure.

AstraZeneca originally studied the molecule as AZD1940/NEO1940. Five early Phase 1 studies included healthy volunteers and people with chronic low-back pain. The historical analgesia program did not produce convincing pain efficacy, but it revealed a dose-related increase in body weight. That observation redirected the asset toward cancer anorexia and cachexia. Artelo later completed the Phase 1b portion of CAReS and is conducting the Phase 2a portion.

By the company’s count, ART27.13 has now been administered across seven clinical studies to more than 280 participants. That exposure base is relevant for common short-term tolerability and pharmacokinetics. It does not answer indication-specific efficacy, long-duration safety, drug-drug interactions in frail cancer populations or the benefit-risk of chronic oral administration in glaucoma.

License economics matter

Artelo’s rights were obtained through an exclusive worldwide license from adMare Bioinnovations, which had acquired the program from AstraZeneca. The agreement includes potential development, regulatory and commercial milestones that can total up to approximately $200 million and mid-to-high single-digit royalties on net sales. Those payments are contingent, but they mean headline future sales would not be wholly retained by Artelo.

The older compound patents had a limited remaining life, making formulation intellectual property important. In 2025 the European Patent Office issued a notice of allowance covering polyethylene-glycol dispersions, including the intended commercial formulation, with expected protection through December 2041. Patent allowance improves negotiating durability; it does not validate efficacy, freedom to operate in every jurisdiction or commercial value by itself.

August 17 US and August 20 Japan notices of allowance extend the intended formulation patent story alongside Europe, with protection expected through 2041. Allowance is not drug approval, issued rights must be checked jurisdiction by jurisdiction, and the small interim CAReS dataset remains the efficacy limitation. Company release →

06CAReS Phase 1b/2a: design, interim data and evidence audit

The Cancer Appetite Recovery Study is a multicenter trial in people with cancer-related anorexia and weight loss. The Phase 2a portion was designed as a double-blind, placebo-controlled study with approximately 40 evaluable patients randomized 3:1 to ART27.13 or placebo for up to 12 weeks. Endpoints include body weight, lean body mass, appetite, quality of life, activity measured with wearable devices and safety. The trial registry lists sites across the United Kingdom and Ireland and was last edited in March 2026.

The September 2025 interim analysis included 18 evaluable participants, primarily with lung or gastrointestinal cancers and not receiving cyclic chemotherapy. The most favorable comparison came from patients who titrated to the highest 1,300-microgram dose. That subgroup contained five treated patients, compared with six placebo patients.

What the interim analysis supports

The direction of weight, lean-mass and activity measures is internally coherent. The strongest effect at the highest dose is compatible with a dose-response hypothesis, and the tolerability description does not show an obvious severe signal. The result is sufficient to justify a larger, properly powered study and partnership discussions. In a company this small, it is also a legitimate source of option value.

What it does not support

Five treated patients do not establish reproducible efficacy. The standard deviations are larger than the mean changes, the sponsor did not provide formal inferential statistics, the cancers were heterogeneous, treatment exposure was shaped by intra-patient titration and the analysis was interim. Weight can also be influenced by fluid, tumor course, corticosteroids, nutrition and anticancer therapy. Lean mass and activity are clinically useful only when measurement methods, missingness and durability are transparent.

The registry currently describes recruitment as closed and the study as ongoing, with a July 2026 overall end date. Artelo’s August update did not publish a full final dataset or announce that all 40 evaluable patients had completed the study. That gap is an important diligence item. Investors should look for a CONSORT-style flow, arm-level baseline characteristics, patient disposition, complete endpoint tables, confidence intervals and a regulatory development plan.

07DREAM glaucoma study: a capital-efficient clinical option

DREAM is a pilot randomized crossover Phase 2 study evaluating whether oral ART27.13 can reduce intraocular pressure in patients with glaucoma or ocular hypertension. Belfast Health and Social Care Trust sponsors the study, Northern Ireland Clinical Trials Unit conducts it, and Glaucoma UK plus the HSC R&D Division provide funding. Artelo supplies investigational capsules. The first patient enrolled on August 10, 2026.

The August 10 company release states 650 micrograms daily; the later August 20 release states 600 micrograms. These issuer descriptions conflict, so the exact current protocol dose requires confirmation from the sponsor. This hub does not treat either figure as a resolved protocol amendment. An oral systemic glaucoma drug must establish a useful pressure effect and acceptable systemic tolerability. August 20 source →

Management expects initial results in Q4 2026. That is a hard catalyst because a study has actually started and third parties are paying most of the experimental cost. It is still a pilot. The key outputs are placebo-adjusted intraocular-pressure change, time of day, crossover washout, within-patient consistency, systemic exposure and tolerability. A positive result could create an ophthalmology partnering path; a negative result would not necessarily invalidate the cancer-cachexia mechanism, because the target tissue and endpoint are different.

The unusually short interval between first patient and expected initial results should be monitored closely. “Q4 data” is company guidance, not a guaranteed public release date or a full development package.

08ART26.12: FABP5 biology, human PK and the translation gap

Fatty acid-binding protein 5 is an intracellular lipid chaperone. Inhibiting FABP5 may reduce transport and metabolism of endocannabinoids and related lipids, increasing endogenous analgesic signaling without directly agonizing cannabinoid receptors or engaging opioid pathways. Artelo positions ART26.12 as a peripherally acting, non-opioid and non-steroidal oral analgesic, initially for chemotherapy-induced peripheral neuropathy.

What the first-in-human study established

The single-ascending-dose Phase 1 study enrolled 49 healthy volunteers. Across the evaluated doses, Artelo reported favorable tolerability, no drug-related adverse events in the blinded dataset, linear dose-dependent absorption and dose-proportional exposure. Plasma concentrations exceeded projected therapeutic exposures derived from animal models, creating room to test clinically relevant doses. Food-effect work also supported dosing flexibility.

Metabolite analysis identified three low-level metabolites representing roughly 7% of total exposure and no human-specific metabolite or associated safety concern. This is useful chemistry and safety information because unexpected human metabolites can complicate development. It remains an early result: single doses in healthy people cannot predict chronic tolerability, interaction with chemotherapy, neuropathy efficacy or rare events.

The Q4 multiple-ascending-dose gate

Artelo plans to begin a multiple-ascending-dose Phase 1 study in Q4 2026. The study should test repeated exposure, accumulation, tolerability and a practical dose range. Biomarker work with ScienceMachine has generated protein and lipid signatures that may reflect target engagement. These are exploratory until prospectively linked to dose and clinical outcomes.

Nonclinical breadth

• CIPN and diabetic neuropathy: animal studies reported reductions in pain behaviors across chemotherapy and metabolic neuropathy models.
• Osteoarthritis: activity was described as comparable to naproxen, with maintained efficacy over four weeks and less gastric-tissue damage in a recent study.
• Spinal-cord injury pain: July 2026 data added another neuropathic model.
• Cancer-induced bone pain: preclinical activity supports oncology-supportive-care relevance.
• Psoriasis, anxiety and oncology: mechanistic datasets create research options, not clinical programs of equal maturity.

The same breadth can become a trap. Positive animal pain studies often fail in humans because model behavior, exposure and endpoints do not capture chronic patient experience. Management should choose a single development path with measurable human proof-of-concept rather than value every disease named by the platform.

09ART12.11: differentiated formulation, still preclinical

ART12.11 is a cocrystal combining cannabidiol with tetramethylpyrazine in a single crystalline form. The formulation is intended to improve solubility, dissolution, bioavailability and consistency relative to conventional CBD. Artelo owns the program rather than licensing it, which makes its future economics cleaner than those of ART27.13.

In animal work, the cocrystal produced higher CBD exposure and favorable behavioral results relative to CBD alone. A chronic-stress rodent model reported antidepressant-like and cognitive effects, including comparisons with sertraline. Other nonclinical work compared pharmacokinetics with Epidiolex. These experiments generate a formulation and mechanism hypothesis; animal behavior is not evidence of antidepressant efficacy in people, and cross-species PK does not establish a clinical advantage over an approved product.

The U.S. composition-of-matter patent is expected to remain enforceable until December 10, 2038, and protection has been granted or validated in 21 additional countries. The Q2 filing lists three issued U.S. patents, one U.S. application, six issued foreign patents and three foreign applications across the relevant portfolio. Patent quantity does not remove the need to demonstrate a clinically meaningful formulation advantage.

Artelo received favorable UK MHRA guidance and has described toxicology and manufacturing preparations for a first-in-human study. The more recent 2026 guidance points to human initiation in the first half of 2027, rather than the older first-half-2026 target. The financing required for toxicology, GMP supply and clinical execution is part of the milestone.

Epidiolex validates that purified CBD can be an approved prescription drug, but its indications are specific seizure disorders—not anxiety or depression. ART12.11 must establish its own safety, dose, pharmacokinetics and efficacy. A better cocrystal is not automatically a better medicine.

10Intellectual property, licenses and retained economics

The Q2 filing describes six issued U.S. patents, ten issued foreign patents and 26 pending applications associated with ART26.12 and the FABP platform. The precise count changed from the year-end filing as applications progressed. Patent estates should be reviewed claim by claim; the number of documents is not a measure of commercial strength.

ART27.13 is the most obvious out-licensing candidate because it has randomized human data and a second clinical indication. A credible transaction would need to disclose territory, upfront cash, development responsibility, milestones and royalties. “Strategic discussions” are not an asset until a counterparty signs and pays. Likewise, the ScienceMachine collaboration may improve research productivity, but no material financial terms or external validation were disclosed.

11Competition and the evidence benchmark ARTL must meet

Cancer cachexia: ponsegromab raises the bar

Pfizer’s GDF-15 antibody ponsegromab is the clearest clinical benchmark. Its randomized Phase 2 study enrolled 187 patients with non-small-cell lung, pancreatic or colorectal cancer and elevated GDF-15. At 12 weeks, the placebo-adjusted body-weight difference was 5.61% at the highest 400 mg dose, with a 95% confidence interval of 2.56% to 8.67%. The study also reported improvements in appetite, physical activity and skeletal-muscle index and was published in the New England Journal of Medicine.

Pfizer has moved into registration-enabling development. The Phase 2b/3 study NCT06989437 targets roughly 982 patients, with a primary completion currently estimated in 2028. ART27.13 may offer oral dosing, peripheral receptor biology and a broader population not selected by GDF-15. It faces a competitor with a much larger randomized evidence base, biomarker strategy and sponsor balance sheet.

CIPN and chronic pain

There is no approved drug that reliably prevents CIPN, and duloxetine is the principal guideline-supported option for established painful CIPN, with modest benefit and tolerability limitations. That unmet need is real. ART26.12 must compete not only with drugs but with dose modification, chemotherapy substitution and heterogeneous neuropathy biology. A non-opioid oral drug would be attractive if a randomized patient trial demonstrates a clinically meaningful pain or function effect.

Glaucoma and psychiatric disease

DREAM enters a treatment landscape with inexpensive generic drops, fixed-dose combinations, sustained-delivery approaches, laser treatment and surgery. An oral therapy must justify systemic exposure. ART12.11 would compete against established antidepressants and anxiolytics and against other cannabinoid formulations; formulation differentiation alone will not overcome the high failure rate of psychiatric trials.

12Q2 2026 financials: filed numbers before narrative

For the six months ended June 30, Artelo recorded a $5.4 million net loss and used $6.2 million of cash in operations. Financing provided $9.8 million, principally through the March private placement. That relationship is the core financial model: operating activity consumes cash, while securities issuance replenishes it.

June cash of $4.198M exceeds the indicative September 4 basic market value of $3.31M by about $0.89M. These dates differ; current cash is not disclosed. The comparison excludes subsequent burn and issuance. Deducting June current liabilities leaves $2.743M before future costs.

EPS and historical transaction figures above retain the pre-August-split filing basis. A one-for-nine restatement would multiply per-share losses by nine; do not compare the reported $0.89 directly with the current share price.

13Cash runway and going concern: the calendar is shorter than the pipeline

The Q2 10-Q states that Artelo needs additional funding to continue operations and that conditions raise substantial doubt about its ability to continue as a going concern within one year after issuance of the financial statements. This is not boilerplate to ignore. It reflects a company with no revenue, $4.2 million of quarter-end liquidity and several clinical programs requiring cash.

A simple arithmetic check illustrates the tension. First-half operating cash use averaged approximately $1.04 million per month. Dividing June 30 cash by that historical average suggests about four months of gross coverage. That is not company guidance and should not be treated as a forecast: working-capital timing, reduced R&D, external study funding, ATM proceeds and new financing can change it. It does show why Q4 milestones and capital access occupy the same window.

After June 30 and through August 11, Artelo sold 386,668 additional shares through the ATM for approximately $354,000 net. The small proceeds relative to the number of shares show how inefficient equity issuance becomes below $1. The ATM can extend operations incrementally, but it also expands the denominator before clinical value is proven.

Runway analysis should distinguish four layers:

• Filed cash: $4.198 million at June 30.
• Known subsequent cash: about $0.354 million of net ATM proceeds through August 11.
• Committed spend: corporate operations and Artelo-funded portions of the MAD, CAReS follow-up and ART12.11 preparations.
• Optional access: ATM, equity line, shelf registration, warrant exercises if the stock rises, partnerships and grants.

Only the first two are cash already received. An unused equity facility is not liquidity until shares are sold, and the cost is dilution. A potential license is not financing until signed.

14Capital structure and dilution: the most important ARTL table

Artelo had approximately 673,000 common shares immediately after the March 10 one-for-three reverse split, based on the December 31 share base adjusted for the split. By June 30 it had 4.188 million shares outstanding, and by August 11 the count reached 4.595 million. The June count was about 6.2 times the split-adjusted year-end base; the August count was about 6.8 times. A historical chart without this denominator change is incomplete.

Using the August 27 basic count and unchanged June warrants gives 4,929,966 + 7,059,620 = 11,989,586 pre-split shares, or approximately 1.332 million post-split equivalents: 2.43 times the approximate basic count. This illustrative exercise scenario excludes options and later issuance and assumes no intervening warrant changes. It is not current dilution; exercise terms and cash proceeds matter.

Pre-funded warrants deserve special attention. They have a nominal exercise price and behave economically like common stock, subject to beneficial-ownership limits. Most March pre-funded warrants had already been exercised by June 30, explaining much of the jump in common shares. Websites that still display 3.49 million shares or an old float understate the current basic count.

The August 2026 reverse split: what it changes and what it does not

On August 26, 2026 Artelo filed a Certificate of Change with the Nevada Secretary of State under NRS 78.209 to effect a one-for-nine reverse stock split. The Form 8-K disclosing it was filed on August 27 under Items 3.03, 5.03, 7.01 and 9.01, with the press release as Exhibit 99.1.

Three mechanical points follow from the filing itself. No shareholder vote was needed: NRS 78.207 lets a Nevada board effect a reverse split without approval when authorized and outstanding shares are reduced proportionally, and that proportional reduction of the authorized capital is exactly what the certificate does. No fractional shares are issued: a holder whose position is not evenly divisible by nine receives one whole share for each fractional share, which rounds up rather than cashing out. Warrants, options and other derivatives adjust automatically under their own terms.

Applying the ratio to the instruments in the table above gives the order of magnitude of the new cap table, as Merlintrader arithmetic rather than company disclosure: the 7,059,620 June warrants become roughly 784,000 with a weighted exercise price near $37.17 instead of $4.13, and the 205,518 options become roughly 22,800 at about $138.69 instead of $15.41. Their moneyness is unchanged. That is the whole point of a split: it renames the units.

What the split does not do is equally important. Each holder’s pro-rata percentage of the company is unchanged, no cash enters the business, no operating problem is solved, and the market value of the equity is unaffected by the mechanics themselves. The company states the purpose is to increase the price per share in order to improve marketability and liquidity. Mechanically, an unchanged $0.711 close on August 26 corresponds to about $6.40 on a nine-times-adjusted basis; that is arithmetic, not a price expectation, and the market sets the actual opening price on August 31.

The split is also the second of 2026. A one-for-three reverse split took effect on March 10, so the cumulative adjustment for the year is one-for-twenty-seven. Anyone comparing a chart, a per-share loss or a historical share count across 2026 has to apply both. Between the 4,595,068 shares outstanding on August 11 and the 4,929,966 in the August 27 filing, the count still rose by roughly 335,000 shares in about two weeks, which is the ATM and equity-line machinery described above continuing to work in the background. A reverse split reduces the number of shares once; it does not stop new ones from being issued.

Why the facilities matter below $1

At the $0.711 close of August 26, raising $5 million before fees would require issuing roughly 7.0 million shares on the pre-split basis—more than the current basic count—if pricing were equal to the market price. Actual discounts, caps and liquidity constraints can make the economics worse. This is illustrative arithmetic, not a forecast of a financing.

Current units and historical tables

The preceding financing and issuance table retains the original pre-August-split units and dates. Since August 31 the comparable common count is approximately 547,774; authorized shares are 55,555,556. June warrants convert mechanically to about 784,402 at a weighted $37.17 strike and options to about 22,835 at $138.69. March common warrants at $3.20 correspond to $28.80 after the split. These are calculations, not a new filed cap table. At $6.04, an illustrative $5M raise at market would require about 827,815 new shares before fees or discounts, about 1.51 times the last disclosed basic count.

15Management, governance and the Solana episode

Gregory Gorgas has served as chief executive officer, president, secretary and a director since 2017. Mark Spring became chief financial officer and treasurer in November 2025 after a long career in life-sciences finance. Connie Matsui chairs the board; other directors bring biotechnology, oncology, finance and commercialization backgrounds. The small organization creates key-person dependence, particularly around the CEO and scientific leadership.

Management should be evaluated against delivered milestones, not breadth of language. Positive items include obtaining third-party funding for DREAM, progressing a first-in-class FABP5 inhibitor into humans and restoring Nasdaq equity compliance. Negative items include repeated financing under severe constraints, timeline slippage, a full CAReS dataset that remains absent after interim promotion and an unusually distracting digital-asset initiative.

The 2025 Solana treasury detour

In August 2025 Artelo announced a $9.475 million PIPE intended to establish Solana’s SOL token as a core reserve asset. The agreement was terminated by mutual consent on August 19 and investor proceeds were returned. Separately, the company had used approximately $250,000 from a June financing to acquire SOL and later sold the position. The 2025 cash-flow statement shows roughly $0.3 million of purchases and $0.2 million of sale proceeds, rounded.

The episode no longer represents a material digital-asset balance. It remains relevant to governance because a cash-constrained clinical-stage biotech briefly proposed combining drug development with crypto treasury exposure, paid transaction costs and used management attention on a strategy that was quickly unwound. Investors can reasonably ask what capital-allocation controls changed afterward.

Nasdaq status

Nasdaq confirmed in April 2026 that Artelo had regained compliance with the minimum-equity and annual-meeting rules. The company is subject to a mandatory one-year panel monitor. The stock traded below $1 before the August reverse split, which can create a separate minimum bid-price issue if it persists for the applicable period.

The one-for-nine reverse split effective August 28 is the standard remedy for that exposure, and what Artelo actually says is narrower than the remedy implies. The Form 8-K and the press release give the purpose as improving the marketability and liquidity of the common stock; neither document mentions a Nasdaq bid-price deficiency notice, a compliance deadline or a hearings panel condition. No such notice was found in the reviewed filings. What can be said is that a nine-times adjustment moves the quoted price well clear of the one-dollar threshold, and that the minimum bid-price rule requires the higher price to hold for a defined number of consecutive sessions before compliance is regained, so the effect is not established on the first day of split-adjusted trading.

Future governance upgrades would include a quantified program-prioritization plan, transparent use of ATM/equity-line proceeds, consistent milestone delivery, disclosure of final CAReS data and capital allocation focused on clinical value.

Craft · FINRA

The August 20 Form 10-Q/A adds an omitted FINRA arbitration disclosure. Craft alleges breach of a right of first refusal tied to the March financing and seeks an $880,000 fee, warrants valued at $880,000, late fees and costs. Artelo filed counterclaims on July 7. The proceeding is ongoing; the requested amounts are not an adjudicated liability. Management expects no material financial-statement impact, but legal expense and diverted resources matter to this cash-constrained company. The amendment does not restate the financial statements. 10-Q/A →

16Ownership, insiders, short interest and market positioning

Ownership data are unusually difficult to interpret because the denominator changed rapidly. The 2025 proxy reported officers and directors at roughly 13% as of February 20, 2026, but that date preceded the March PIPE, millions of pre-funded-warrant exercises and the ATM. Applying that percentage to the August share count would be wrong.

A Schedule 13G filed August 13 by Intracoastal Capital, Mitchell Kopin and Daniel Asher reported beneficial ownership tied to 173,914 warrant shares, or approximately 4.8% under the filing’s calculation as of a June 30 event. The filing is passive and states the holder had fallen to or below 5%. It is a useful current ownership disclosure, not evidence of broad institutional sponsorship.

Third-party services showed institutional and insider percentages based on stale share counts. The same problem affects short-float ratios. Mid-July short interest was reported around 169,000 shares with roughly one day to cover, but dividing it by an outdated float can produce a misleading percentage. In a recapitalizing micro-cap, absolute share counts and settlement dates are more reliable than headline percentages.

The August 12 closing price was $0.733, near a 52-week low and down more than 97% over one year on a split-adjusted market-data series. Volume can spike around press releases and financing. The stock’s very small market value means modest order flow can cause large percentage moves; liquidity risk works in both directions.

There is no usable analyst consensus. Recent visible ratings were holds, and split-adjusted target aggregations can contain stale numbers that bear no relation to the current cap table. A target is excluded rather than presented with false precision.

Armistice Capital and Steven Boyd’s August 14 Schedule 13G/A reports zero beneficial shares as of June 30. This is a dated ownership disclosure, not proof that every later exposure is zero. The latest Form 4 filings in the SEC feed remain July 21; no subsequent insider transaction filing was found in this review. 13G/A →

StockTwits

September 5 connector: normalized sentiment 77/100, EXTREMELY_BULLISH; activity 78/100, EXTREMELY_HIGH; 10,604 watchers. The sampled posts focus on microfloat, squeeze expectations and financing. These are retail narratives, not evidence of an announced raise or clinical success. Marketstack supplies the dated close: $6.04 on September 4, −2.89%, volume 27,654. The StockTwits extended-session quote is a different observation.

17Valuation framework: why cash is not enough and rNPV is premature

At the September 4 close, $6.04 multiplied by the approximately 547,774 split-adjusted shares disclosed in August implies about $3.31 million of basic equity value. This is an estimate using the last filed count, not a live fully diluted capitalization. June cash was $4.20 million, and current liabilities were $1.46 million. A simplistic screen therefore shows cash above market value and about $2.74 million of cash after current liabilities. The screen ignores future burn, trial obligations, transaction costs and the capital needed to reach a value-creating readout.

Enterprise value is also unstable because the basic share count continues to change and warrants become relevant at higher prices. A fully diluted calculation at today’s price would overstate current dilution from out-of-the-money warrants; ignoring them would understate the denominator in an upside scenario. The solution is scenario analysis, not one headline multiple.

Base path

Artelo delivers one or both Q4 events but neither creates a near-term license. The company raises additional equity to continue the MAD program and prepare patient studies. Scientific optionality improves while common shareholders absorb another denominator increase. This is the most important distinction in pre-revenue micro-cap biotech: successful experiments do not automatically produce successful per-share outcomes.

A responsible rNPV would require a target product profile, registrational design, probability by development stage, addressable biomarker population, pricing, uptake curve, margin, license payments, development cost and financing path. Artelo has not disclosed enough of those inputs. The absence of a numerical target is analytical discipline, not a lack of a thesis.

Upgrade conditions: complete CAReS data with inferential statistics; signed partnership with meaningful upfront cash; clean MAD execution; positive DREAM pharmacodynamics; and financing that improves runway without transferring most upside. Downgrade conditions: milestone slippage, weak DREAM effect, new safety findings, sub-$1 facility issuance at scale or evidence that a pivotal cachexia study cannot be financed.

18Merlintrader Health Score: science above the balance sheet

The Merlintrader Health Score is an editorial framework, not a quantitative investment rating, recommendation or price target. It can change immediately after new filings, financing or clinical data.

19Catalyst calendar: events, status and what actually matters

The calendar contains both scientific and capital catalysts because they are inseparable. A positive pilot readout followed immediately by discounted financing may still produce a weak per-share result. Conversely, a modest clinical signal paired with non-dilutive partnership funding could materially improve the equity setup.

20Falsifiers, red flags and the next diligence questions

Clinical falsifiers

• DREAM does not show a consistent intraocular-pressure effect or produces systemic tolerability problems.
• The ART26.12 MAD study does not begin in Q4, reveals accumulation or safety issues, or cannot reach exposures associated with preclinical activity.
• Final CAReS data shrink the top-dose effect, show imbalanced attrition or fail to support activity and function alongside weight.
• Regulators require a much larger or longer cachexia program than a partner is willing to finance.
• ART12.11 toxicology or manufacturing delays first-in-human work again.

Financial and governance falsifiers

• Large ATM or equity-line draws below $1 increase shares faster than cash runway.
• New financing adds reset provisions, variable-price instruments or warrants that dominate future upside.
• The company does not quantify how it will fund the MAD and subsequent patient proof-of-concept.
• Management promotes new indications faster than it retires lower-priority spending.
• Nasdaq compliance becomes a recurring driver of reverse splits and authorized-share changes.

Questions for the next call or filing

1. How many CAReS patients completed 12 weeks in each arm, and when will the complete table be released?
2. What endpoint and population would regulators accept for the next ART27.13 study?
3. What portion of a future study must Artelo fund before a partner decision?
4. What are the MAD cohort sizes, duration, doses and projected cash cost?
5. How much unrestricted cash is available after August ATM sales and committed vendor payments?
6. What minimum runway does the board require before starting another internally funded trial?
7. Which equity facility will be used first, under what price/volume limits, and how will investors be informed?

21Operational monitoring checklist

A useful investor dashboard should update the share count before updating the stock chart. For ARTL, the denominator can change the investment result more than a small change in quarterly expense.

22Merlintrader research coverage

This is the first dedicated full-length Artelo Biosciences stock hub identified in the Merlintrader.com archive as of the August 13 review. It consolidates the current filing, all three main programs, capital structure and catalyst logic into one living page. Future earnings, financing and clinical releases should update this page rather than create disconnected summaries.

For cross-company context, use the Top Ten Biotech Stocks Right Now and the free catalyst calendar linked below.

23Bottom line: compelling experiments, distressed financing math

Artelo is more scientifically substantive than its approximately $3.31 million indicative basic market value at the September 4 close suggests. ART27.13 has a real human history and an intriguing randomized signal. DREAM is a clever externally funded experiment. ART26.12 is a differentiated mechanism with clean early human pharmacology and broad animal evidence. ART12.11 provides wholly owned formulation optionality.

The common equity is not simply those assets divided by the share count of the day, 4.930 million before the split and about 547,774 after it. It is those assets minus the cash required to reach proof, subject to approximately 784,402 split-equivalent warrants based on the June balance, an ATM, an equity line and a history of rapid recapitalization. The Q2 filing makes the conflict explicit: $4.2 million of cash after $6.2 million of first-half operating use, no revenue and substantial doubt about continuing operations.

The best near-term path is not another promotional indication. It is a clean DREAM readout, an on-time MAD start, full CAReS disclosure and a partner that brings upfront cash. Until at least one of those events improves financing quality, the case rests on unproven peak-sales assumptions rather than on disclosed evidence.